fisetin: receipt-backed evidence fronts

Source literature boundary memo

Research question

What evidence fronts does fisetin occupy across animal model, cell or in-vitro model, and chemistry/formulation, and what remains untested?

Selection criteria

The latest Longevity / anti-aging research discovery pass ranked fisetin as source-rich. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence [primary; 2023] doi:10.1111/acel.14060
  • Finding: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells
  • Population: senescent human umbilical vein endothelial cells (HUVECs)
  • Intervention/exposure: fisetin
  • Comparator: nonsenescent control HUVECs (IC50 7.0 ± 0.4 μM)
• Improving solubility of fisetin by cocrystallization [primary; 2014] doi:10.1039/c4ce01713g
  • Finding: a 2.5-fold increase of fisetin solubility was achieved for FisNam
  • Population: fisetin cocrystals
  • Intervention/exposure: fisetin–nicotinamide 1:1 cocrystal (FisNam)
  • Comparator: pure fisetin
• Fisetin Protects PC12 Cells from Tunicamycin-Mediated Cell Death via Reactive Oxygen Species Scavenging and Modulation of Nrf2-Driven Gene Expression, SIRT1 and MAPK Signaling in PC12 Cells [primary; 2017] doi:10.3390/ijms18040852
  • Finding: Fisetin (<20 µM) restored cell viability and repressed apoptosis, autophagy and ROS production in Tm-treated cells.
  • Population: PC12 cells
  • Intervention/exposure: fisetin (<20 µM)
  • Comparator: tunicamycin-treated cells
• Antiproliferative Mechanisms of the Flavonoids 2,2′-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells [primary; 2010] doi:10.1080/01635581003605524
  • Finding: DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h.
  • Population: PC3 human prostate cancer cells
  • Intervention/exposure: DHC and fisetin (1-50 μM)
• Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle [primary; 2022] doi:10.18632/aging.204275
  • Finding: We administrated fisetin to mdx/utro(-/-) mice for 4 weeks and observed reduced senescent immune cells and improved muscle phenotypes.
  • Population: mdx/utro(-/-) mice
  • Intervention/exposure: fisetin administration

Source synthesis

Answer: this 5-source primary bundle supports a receipt-backed scoping note for fisetin, spanning 2010-2023. The source facts cover 5 population context(s) and 5 intervention/exposure context(s). The bounded signal is context separation across animal model, cell or in-vitro model, and chemistry/formulation: the bundle identifies what has been measured and where the evidence separates, without establishing a causal, clinical, species-translated, or mechanistically integrated intervention claim. Representative source-extracted findings include: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; a 2.5-fold increase of fisetin solubility was achieved for FisNam; Fisetin (<20 µM) restored cell viability and repressed apoptosis, autophagy and ROS production in Tm-treated cells.

Context separation

The selected receipts group because each carries a fact-level extraction for fisetin; they separate by context (animal model, cell or in-vitro model, and chemistry/formulation), so they are not interchangeable evidence for one endpoint.

Boundary limits

Source-literature boundary for fisetin: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.

Next gaps

A stronger memo needs one matched population/model, intervention or exposure, comparator, and endpoint. If fisetin is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing animal model, cell or in-vitro model, and chemistry/formulation.